IDEAS home Printed from https://ideas.repec.org/f/pko840.html
   My authors  Follow this author

Ying Kong

Personal Details

First Name:Ying
Middle Name:
Last Name:Kong
Suffix:
RePEc Short-ID:pko840
[This author has chosen not to make the email address public]
Terminal Degree:2000 Department of Economics; Carleton University (from RePEc Genealogy)

Affiliation

Department of Economics
York University

Toronto, Canada
http://econ.laps.yorku.ca/

(416) 736-5083
(416) 736-5987
4700 Keele Street, Toronto, Ontario, M3J 1P3
RePEc:edi:dyorkca (more details at EDIRC)

Research output

as
Jump to: Working papers Articles

Working papers

  1. Ying KONG & Hsiao-Chan WANG, 2008. "A Game Theory Model of Inverse Pricing Strategy," EcoMod2008 23800066, EcoMod.
  2. Ying Kong & Gervan Fearon, 2006. "A Game Theory Model of Welfare Analysis for Price Change of Imports," EcoMod2006 272100045, EcoMod.
  3. Zhiqi Chen & Ying Kong, 2001. "Price Dispersion in a Model of Identical Agents with Perfect Information," Carleton Economic Papers 01-04, Carleton University, Department of Economics, revised Feb 2004.

Articles

  1. Ferrara, Ida & Kong, Ying, 2008. "Can health insurance coverage explain the generic competition paradox?," Economics Letters, Elsevier, vol. 101(1), pages 48-52, October.
  2. Ying Kong & James Seldon, 2006. "Pseudo-Generic Products and Barriers to Entry in Pharmaceutical Markets: Reply," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 28(2), pages 189-193, March.
  3. Ying Kong, 2004. "The price premium of generic to brand-names and pharmaceutical price index," Applied Economics, Taylor & Francis Journals, vol. 36(7), pages 731-737.
  4. Ying Kong & James R. Seldon, 2004. "Pseudo-Generic Products and Barriers to Entry in Pharmaceutical Markets," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 25(1), pages 71-86, August.
  5. Ying Kong, 2003. "Persistent dumping, competition and welfare," The Journal of International Trade & Economic Development, Taylor & Francis Journals, vol. 12(1), pages 19-37.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

    Sorry, no citations of working papers recorded.

Articles

  1. Ferrara, Ida & Kong, Ying, 2008. "Can health insurance coverage explain the generic competition paradox?," Economics Letters, Elsevier, vol. 101(1), pages 48-52, October.

    Cited by:

    1. Herr, Annika & Suppliet, Moritz, 2012. "Pharmaceutical prices under regulation: Tiered co-payments and reference pricing in Germany," DICE Discussion Papers 48, University of Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
    2. Ferrara, Ida & Missios, Paul, 2012. "Pricing of drugs with heterogeneous health insurance coverage," Journal of Health Economics, Elsevier, vol. 31(2), pages 440-456.
    3. Fernando Antoñanzas & Carmelo Juárez-Castelló & Roberto Rodríguez-Ibeas, 2011. "Innovation, loyalty and generic competition in pharmaceutical markets," SERIEs: Journal of the Spanish Economic Association, Springer;Spanish Economic Association, vol. 2(1), pages 75-95, March.
    4. Suppliet, Moritz & Herr, Annika, 2016. "Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets," Other publications TiSEM 6430293b-fde9-4f91-ab35-3, Tilburg University, School of Economics and Management.
    5. Ivan Moreno-Torres, 2011. "Generic drugs in Spain: price competition vs. moral hazard," Working Papers XREAP2011-04, Xarxa de Referència en Economia Aplicada (XREAP), revised May 2011.
    6. Nabin Munirul Haque & Mohan Vijay & Nicholas Aaron & Sgro Pasquale M., 2012. "Therapeutic Equivalence and the Generic Competition Paradox," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 12(1), pages 1-26, November.
    7. Julen Castillo‐Apraiz & Jesus Matey, 2020. "Customizing competitive strategy to entry timing: Implications for firm performance in the pharmaceutical industry," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 41(6), pages 976-985, September.

  2. Ying Kong, 2004. "The price premium of generic to brand-names and pharmaceutical price index," Applied Economics, Taylor & Francis Journals, vol. 36(7), pages 731-737.

    Cited by:

    1. Laurent Granier & Sébastien Trinquart, 2010. "Predation in Off-Patent Drug Markets," Working Papers 1027, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon.
    2. Aidan Hollis, 2005. "How do Brands’ “Own Generics” Affect Pharmaceutical Prices?," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 27(4), pages 329-350, December.

  3. Ying Kong & James R. Seldon, 2004. "Pseudo-Generic Products and Barriers to Entry in Pharmaceutical Markets," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 25(1), pages 71-86, August.

    Cited by:

    1. Laurent Granier & Sébastien Trinquart, 2010. "Predation in Off-Patent Drug Markets," Working Papers 1027, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon.
    2. David Reiffen & Michael R. Ward, 2007. "'Branded Generics' as a strategy to limit cannibalization of pharmaceutical markets," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 251-265.
    3. Vasco Rodrigues & Ricardo Gonçalves & Hélder Vasconcelos, 2014. "Anti-Competitive Impact of Pseudo-Generics," Journal of Industry, Competition and Trade, Springer, vol. 14(1), pages 83-98, March.
    4. Kurt R. Brekke & Chiara Canta & Odd Rune Straume, 2015. "Reference pricing with endogenous generic entry," NIPE Working Papers 2/2015, NIPE - Universidade do Minho.
    5. Regan, Tracy L., 2008. "Generic entry, price competition, and market segmentation in the prescription drug market," International Journal of Industrial Organization, Elsevier, vol. 26(4), pages 930-948, July.
    6. Aidan Hollis, 2005. "How do Brands’ “Own Generics” Affect Pharmaceutical Prices?," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 27(4), pages 329-350, December.
    7. Yunyun Wan, 2018. "Brand Loyalty and Generic Entry: Why Do Brand-Name Drug Companies Launch Their Own Generics?," The Japanese Economic Review, Springer, vol. 69(3), pages 340-346, September.
    8. Paul Grootendorst, 2007. "Effects of 'Authorized-Generics' on Canadian Drug Prices," Social and Economic Dimensions of an Aging Population Research Papers 201, McMaster University.
    9. de Vries, A.G.B. & Pennings, H.P.G. & Block, J.H., 2013. "Trademark or patent? The effects of market structure, customer type and venture capital financing on start-ups' IP decisions," ERIM Report Series Research in Management ERS-2013-002-STR, Erasmus Research Institute of Management (ERIM), ERIM is the joint research institute of the Rotterdam School of Management, Erasmus University and the Erasmus School of Economics (ESE) at Erasmus University Rotterdam.
    10. Ramello, Giovanni B., 2008. "Semiotica, diritto e mercato. Economia del marchio nel terzo millenio," POLIS Working Papers 102, Institute of Public Policy and Public Choice - POLIS.
    11. Ying Kong, 2009. "Competition between brand‐name and generics – analysis on pricing of brand‐name pharmaceutical," Health Economics, John Wiley & Sons, Ltd., vol. 18(5), pages 591-606, May.
    12. Farasat A.S. Bokhari & Franco Mariuzzo & Arnold Polanski, 2020. "Entry limiting agreements: First mover advantage, authorized generics and pay-for-delay deals," Working Paper series, University of East Anglia, Centre for Competition Policy (CCP) 2015-05v4, Centre for Competition Policy, University of East Anglia, Norwich, UK..
    13. Marjit, Sugata & Kabiraj, Tarun & Dutta, Arijita, 2009. "Strategic Under-utilization of Patents and Entry Deterrence: The Case of Pharmaceutical Industry," MPRA Paper 19157, University Library of Munich, Germany.
    14. Ricardo Gonçalves & Vasco Rodrigues & Hélder Vasconcelos, 2015. "Reference pricing in the presence of pseudo-generics," International Journal of Health Economics and Management, Springer, vol. 15(3), pages 281-305, September.
    15. Farasat A. S. Bokhari & Franco Mariuzzo & Arnold Polanski, 2020. "Entry limiting agreements: First‐mover advantage, authorized generics, and pay‐for‐delay deals," Journal of Economics & Management Strategy, Wiley Blackwell, vol. 29(3), pages 516-542, July.
    16. Ying Kong & James Seldon, 2006. "Pseudo-Generic Products and Barriers to Entry in Pharmaceutical Markets: Reply," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 28(2), pages 189-193, March.

  4. Ying Kong, 2003. "Persistent dumping, competition and welfare," The Journal of International Trade & Economic Development, Taylor & Francis Journals, vol. 12(1), pages 19-37.

    Cited by:

    1. Patricia Tovar, 2014. "External tariffs under a free-trade area," The Journal of International Trade & Economic Development, Taylor & Francis Journals, vol. 23(5), pages 656-681, August.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 1 paper announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-GTH: Game Theory (1) 2014-10-13
  2. NEP-MIC: Microeconomics (1) 2014-10-13

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Ying Kong should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.